Short-Term Outcomes of an Investigational Hybrid Polymer–Hyaluronic Acid Filler for Nonsurgical Rhinoplasty: An Uncontrolled Pilot Study Authors: Hsin-Kai Chen, Hsi-Cheng Liu, Heng-Ju Lin, Donghui Wu Published: 2026 ABSTRACT BackgroundNonsurgical rhinoplasty using hyaluronic acid fillers provides minimally invasive correction of selected nasal contour irregularities. Hybrid formulations incorporating biodegradable polymeric microspheres have been developed to provide immediate volumetric correction together with additional structural support; however, clinical evidence regarding these formulations remains limited.ObjectiveTo evaluate the short-term safety, tolerability, preliminary aesthetic effectiveness, and patient satisfaction associated with an investigational hybrid filler containing cross-linked hyaluronic acid, polycaprolactone, and polylactic acid microspheres.MethodsThis prospective, single-center, uncontrolled pilot study included 150 adults undergoing nonsurgical rhinoplasty. Participants were assessed at baseline, Day 2, Week 2, Month 1, and Month 3. Outcomes included treatment-emergent adverse events, Global Aesthetic Improvement Scale ratings, patient satisfaction, nasal tip projection, dorsal height, and procedural characteristics.ResultsImproved or Very Improved GAIS ratings were observed in 86.7% of participants at Month 1 and 83.3% at Month 3. Satisfaction scores of 4–5 were reported by 90.0% at Month 1 and 86.7% at Month 3. Tip projection increased by more than 1.5 mm in 70.0%, while dorsal height increased by more than 2.0 mm in 63.3%. Mild events included transient erythema in 3.3%, minor bruising in 13.3%, and injection-site pain with a VAS score greater than 5 in 10.0%. No serious or treatment-requiring adverse event, vascular compromise, skin necrosis, visual disturbance, infection, granuloma, delayed inflammatory reaction, or filler migration was observed during three months of follow-up.ConclusionThe investigational formulation demonstrated favorable short-term tolerability and early aesthetic improvement in an uncontrolled pilot setting. These findings do not establish comparative effectiveness, long-term durability, tissue integration, or long-term biocompatibility. Controlled studies with extended follow-up are required. Introduction The growing demand for minimally invasive aesthetic procedures has transformed contemporary cosmetic medicine, with patients increasingly seeking treatments that provide effective aesthetic enhancement while minimizing recovery time and procedural risk. Among these approaches, nonsurgical rhinoplasty (NSR) using hyaluronic acid (HA)-based fillers has emerged as a widely accepted alternative to surgical rhinoplasty for the correction of selected nasal contour irregularities and aesthetic concerns.1–3 Owing to its relative simplicity, reversibility, and ability to achieve immediate cosmetic improvement, HA-based NSR has gained substantial popularity worldwide, with large clinical series reporting high patient satisfaction and favorable safety outcomes.4,5 The success of NSR largely depends on the rheological properties of the filler material, including elasticity, cohesivity, and resistance to degradation, which collectively influence structural support, contour stability, and treatment longevity.6–8 Advances in filler technology have led to the development of highly cohesive cross-linked HA formulations capable of providing predictable projection and contour definition in anatomically challenging regions such as the nasal dorsum and tip.9–11 Despite these improvements, the unique vascular anatomy of the nose continues to present procedural challenges, emphasizing the importance of appropriate patient selection, anatomical expertise, and safe injection techniques to minimize complications.12–14 Cross-linked hyaluronic acid fillers are widely used for nonsurgical rhinoplasty because they provide immediate volumetric correction and can potentially be dissolved using hyaluronidase when clinically indicated. Their structural performance is influenced by elasticity, cohesivity, viscosity, injected volume, anatomical placement, and injection technique. Conventional HA fillers also have a larger clinical evidence base than hybrid polymer-containing formulations. Therefore, the potential advantages of a new hybrid filler cannot be assumed solely from its material composition and should be evaluated through controlled clinical comparison with established HA products. The investigated formulation differs from conventional HA-only fillers because it contains biodegradable polycaprolactone and polylactic acid microspheres in addition to cross-linked hyaluronic acid. The HA component was intended to provide immediate volumetric augmentation, while the polymeric components were incorporated to provide gradual structural support during biodegradation. However, the present study did not directly evaluate polymer degradation, collagen production, tissue integration, or regenerative activity. Therefore, any proposed biological contribution of the polymer microspheres should be regarded as theoretical and cannot be confirmed from the current clinical observations. In parallel with advances in injection methodology, innovations in biomaterial engineering have expanded the scope of injectable soft-tissue augmentation. Hybrid formulations that combine cross-linked HA with biodegradable polymeric components have been developed to enhance structural support and improve tissue integration. These materials are intended not only to provide immediate volumization but also to promote tissue remodeling through progressive collagen deposition and extracellular matrix reorganization.15,16 Preliminary evidence suggests that such hybrid fillers may offer improved durability and contour stability compared with conventional HA fillers, particularly in areas exposed to repetitive mechanical stress, such as the nasal tip.17,18 Clinical studies evaluating HA-based fillers for nonsurgical rhinoplasty have consistently demonstrated favorable aesthetic outcomes, high patient satisfaction, and low rates of serious adverse events.19–22 However, evidence regarding the clinical performance of hybrid polymer–HA formulations remain limited. In particular, there is a lack of prospective clinical data evaluating their short-term safety, tolerability, and effectiveness in nonsurgical nasal contouring. The present prospective pilot study was conducted to evaluate the short-term safety, tolerability, and preliminary aesthetic effectiveness of an investigational injectable formulation containing cross-linked hyaluronic acid and biodegradable PCL and PLA microspheres for nonsurgical rhinoplasty. It was hypothesized that the formulation would demonstrate acceptable local tolerability and measurable early improvement in nasal contour during three months of follow-up. The study was not designed to establish superiority over existing HA fillers or to assess long-term durability, tissue remodelling, polymer degradation, or long-term biocompatibility. Materials and Methods Study Design and Ethical Approval This prospective, single-center, uncontrolled pilot clinical study was conducted at Xiamen Siming Ruilijia Plastic Surgery Clinic to evaluate the short-term safety, tolerability, and preliminary aesthetic effectiveness of an investigational hybrid injectable formulation containing regenerated biodegradable polymeric microspheres and cross-linked hyaluronic acid. No control or comparator filler group was included. Therefore, the study was designed to provide preliminary descriptive evidence and was not intended to determine superiority or comparative effectiveness against commercially available HA fillers. No formal a priori sample-size or statistical power calculation was performed because the investigation was designed as an exploratory pilot study. A total of 150 eligible participants were enrolled to provide preliminary descriptive information regarding common short-term local reactions, treatment tolerability, patient satisfaction, and early aesthetic outcomes. Consequently, all inferential findings were considered exploratory and hypothesis-generating. Participant Selection Inclusion Criteria Participants were eligible if they: Were 21–55 years of age.Requested nonsurgical aesthetic nasal contour correction.Had Fitzpatrick skin types I–IV.Were in good general health.Provided written informed consent and agreed to attend all scheduled follow-up visits. Were 21–55 years of age. Were 21–55 years of age. Requested nonsurgical aesthetic nasal contour correction. Requested nonsurgical aesthetic nasal contour correction. Had Fitzpatrick skin types I–IV. Had Fitzpatrick skin types I–IV. Were in good general health. Were in good general health. Provided written informed consent and agreed to attend all scheduled follow-up visits. Provided written informed consent and agreed to attend all scheduled follow-up visits. Exclusion Criteria Participants were excluded if they had: Previous surgical rhinoplasty or permanent nasal implants.Active infection, inflammation, or dermatologic disease involving the treatment area.Known hypersensitivity to hyaluronic acid, lidocaine, or any component of the investigational product.Pregnancy or lactation.Use of anticoagulants, corticosteroids, or immunosuppressive medications within four weeks before treatment.A history of connective tissue disorders or keloid formation. Previous surgical rhinoplasty or permanent nasal implants. Previous surgical rhinoplasty or permanent nasal implants. Active infection, inflammation, or dermatologic disease involving the treatment area. Active infection, inflammation, or dermatologic disease involving the treatment area. Known hypersensitivity to hyaluronic acid, lidocaine, or any component of the investigational product. Known hypersensitivity to hyaluronic acid, lidocaine, or any component of the investigational product. Pregnancy or lactation. Pregnancy or lactation. Use of anticoagulants, corticosteroids, or immunosuppressive medications within four weeks before treatment. Use of anticoagulants, corticosteroids, or immunosuppressive medications within four weeks before treatment. A history of connective tissue disorders or keloid formation. A history of connective tissue disorders or keloid formation. Investigational Product The investigational filler consisted of cross-linked hyaluronic acid at a concentration of 25 mg/mL combined with biodegradable polycaprolactone and polylactic acid microspheres measuring approximately 20–40 μm. The microspheres were suspended within a physiological carrier matrix. The HA component was intended to provide immediate volumetric augmentation, while the polymeric microspheres were intended to provide gradual structural support during biodegradation. The formulation was manufactured by Ruilijia Biomedical Technology Co., Ltd., China, under quality-controlled manufacturing conditions. Product sterility was verified through manufacturer-conducted sterility testing before clinical use. At the time of the study, the formulation was investigational and had not received commercial marketing authorization. It was evaluated within the present ethics-approved clinical investigation after written informed consent. The exact PCL-to-PLA proportion, complete carrier composition, hyaluronic acid cross-linking chemistry, rheological values, and full preclinical safety dossier were not available in the study records used for the present analysis. These parameters were therefore not independently assessed or reported. This incomplete product characterization limits reproducibility and interpretation of the proposed material-specific biological effects. Injection Procedure All procedures were performed in an outpatient clinical setting under aseptic conditions by experienced aesthetic physicians. A topical 5% lidocaine cream was applied approximately 30 minutes before treatment. Depending on the anatomical requirements and the treating physician’s clinical judgement, injections were performed using either a 27-gauge blunt cannula or a 30-gauge sharp needle. The treated anatomical areas included the nasal dorsum, nasal tip, supratip region, and radix. Product placement was performed using microdroplet and depot injection techniques according to individual anatomical characteristics and aesthetic objectives. The total injected volume ranged from 0.3 to 1.2 mL, with a mean volume of 0.85 ± 0.23 mL. The study records did not contain standardized documentation of the exact injection plane, entry point, aliquot size, volume administered to each nasal subunit, formal criteria for choosing a needle or cannula, or the exact number and years of experience of the injectors. These procedural details could not be reconstructed retrospectively and are acknowledged as limitations affecting reproducibility. Following treatment, participants were instructed to avoid excessive pressure on the nose, strenuous physical activity, and prolonged sun exposure for 48 hours. Outcome Measures Primary Outcome: Clinical Safety and Tolerability The primary outcome was the assessment of short-term clinical safety and treatment tolerability. Clinical safety and local tissue compatibility were assessed through the occurrence of adverse tissue reactions, including: Persistent erythema.Edema and bruising.Induration or nodule formation.Granuloma formation.Infection or abscess formation.Filler migration or clinically significant asymmetry.Delayed inflammatory or hypersensitivity reactions.Vascular compromise, skin necrosis, visual symptoms, or other serious complications. Persistent erythema. Persistent erythema. Edema and bruising. Edema and bruising. Induration or nodule formation. Induration or nodule formation. Granuloma formation. Granuloma formation. Infection or abscess formation. Infection or abscess formation. Filler migration or clinically significant asymmetry. Filler migration or clinically significant asymmetry. Delayed inflammatory or hypersensitivity reactions. Delayed inflammatory or hypersensitivity reactions. Vascular compromise, skin necrosis, visual symptoms, or other serious complications. Vascular compromise, skin necrosis, visual symptoms, or other serious complications. Pain intensity was assessed using a 10-point Visual Analog Scale (VAS) immediately at Day 2 follow-up. Secondary Outcomes: Clinical Effectiveness and Patient Satisfaction Secondary outcomes included: Standardized digital photographs were obtained at baseline and at each scheduled follow-up visit. Global Aesthetic Improvement Scale assessments were performed by independent evaluators using the categories Very Improved, Improved, No Change, or Worse. The study documentation did not specify whether the evaluators were blinded to the treatment visit or photographic sequence. Changes in nasal tip projection and dorsal height were assessed in millimetres using the clinic’s standardized anthropometric assessment protocol and standardized digital photographs. An increase greater than 1.5 mm in nasal tip projection and greater than 2.0 mm in dorsal height was used as a descriptive threshold for reporting anatomical improvement. These thresholds were study-specific operational cutoffs and were not validated minimal clinically important differences. The original study records did not provide detailed information regarding the exact anatomical landmarks, photographic calibration method, measurement software, repeated-measurement procedure, or intraobserver and interobserver reliability. The absence of these details limits reproducibility and should be considered when interpreting the anatomical outcomes. Follow-Up Schedule The three-month follow-up period was selected to evaluate acute and subacute adverse events, treatment tolerability, early aesthetic improvement, and short-term maintenance of correction. It was insufficient to evaluate long-term durability, polymer degradation, collagen-mediated remodelling, delayed inflammatory reactions, foreign-body granuloma, long-term migration, or long-term biocompatibility. These outcomes were beyond the scope of the present pilot study. Ethical and Regulatory Considerations This investigation was conducted as an exploratory pilot clinical study intended to evaluate the short-term safety, tolerability, and preliminary effectiveness of the investigational filler formulation. The study was not designed as a pivotal regulatory registration trial and should not be interpreted as evidence supporting product approval or commercial authorization. All participants voluntarily provided written informed consent before participation. Participant confidentiality, adverse-event monitoring, data collection, and study conduct were performed under the oversight of the institutional ethics committee and in accordance with the ethical principles of the Declaration of Helsinki. Statistical Analysis Statistical analyses were performed using SPSS version 26.0. Continuous variables were summarized as mean ± standard deviation, whereas categorical variables were reported as frequencies and percentages. Comparisons between categorical variables were performed using the chi-square test or Fisher’s exact test, as appropriate. Associations between continuous variables were explored using Pearson correlation analysis. Within-participant changes in pain scores between the immediate post-treatment assessment and Day 2 were evaluated using a paired analysis. The study was exploratory, and no formal a priori power calculation was performed. Therefore, all inferential analyses were considered hypothesis-generating. A two-sided p-value of less than 0.05 was considered statistically significant. Results Participant Demographics and Baseline Characteristics 150 participants were enrolled and completed the study. The largest proportion of participants belonged to the 31–40 years age group (40.0%, n = 60), followed by the 21–30 years group (30.0%, n = 45) and the 41–55 years group (30.0%, n = 45). Treatments findings were not statistically different between the age categories (p = 0.78). The majority of the study subjects were females (70.0%, n = 105) while males were 30.0% (n = 45). Fitzpatrick skin type III was the most common (43.3%, n = 65), followed by type II (26.7%, n = 40), type IV (23.3%, n = 35), and type I (6.7%, n = 10). There were no significant differences in treatment effectiveness and tolerability among skin types (p = 0.61) (Table 1).Table 1Participant Demographics and Baseline Characteristics (n = 150)CharacteristicCategoryFrequency (n)Percentage (%)Age Group21–30 years4530.031–40 years6040.041–55 years4530.0GenderFemale10570.0Male4530.0Fitzpatrick TypeI106.7II4026.7III6543.3IV3523.3 Table 1Participant Demographics and Baseline Characteristics (n = 150)CharacteristicCategoryFrequency (n)Percentage (%)Age Group21–30 years4530.031–40 years6040.041–55 years4530.0GenderFemale10570.0Male4530.0Fitzpatrick TypeI106.7II4026.7III6543.3IV3523.3 Participant Demographics and Baseline Characteristics (n = 150) Safety and Tolerability All 150 participants completed the scheduled follow-up. Reported treatment-emergent events were mild, localized, and self-limited. Transient erythema lasting less than 48 hours occurred in 5 participants, minor bruising occurred in 20 participants, and injection-site pain with a VAS score greater than 5 was reported by 15 participants. Immediately after treatment, 15 of 150 participants (10.0%) experienced injection-site pain rated greater than 5 on a 0-to-10 visual analog scale (VAS), indicating moderate-to-severe pain (Table 2).Table 2Short-Term Safety and Tolerability Outcomes Following Nonsurgical Rhinoplasty (n = 150)Safety OutcomeAssessment TimeFrequency, nPercentage, %Transient erythema lasting <48 hoursEarly post-treatment period53.3Injection-site pain, VAS >5Immediately after treatment1510.0Minor bruisingEarly post-treatment period2013.3Mild asymmetry not requiring interventionMonth 353.3Filler migrationThrough Month 300.0Delayed inflammatory reactionThrough Month 300.0Granuloma or persistent noduleThrough Month 300.0Infection or abscessThrough Month 300.0Vascular compromiseThrough Month 300.0Skin necrosisThrough Month 300.0Visual disturbanceThrough Month 300.0Serious adverse eventThrough Month 300.0Medical or surgical intervention requiredThrough Month 300.0Notes: Participants could experience more than one mild treatment-emergent event; therefore, the event categories were not mutually exclusive. All reported events were mild, localized, and self-limiting. No serious or treatment-requiring complication was observed during the three-month follow-up.Abbreviations: SD, standard deviation; VAS, Visual Analog Scale. Table 2Short-Term Safety and Tolerability Outcomes Following Nonsurgical Rhinoplasty (n = 150)Safety OutcomeAssessment TimeFrequency, nPercentage, %Transient erythema lasting <48 hoursEarly post-treatment period53.3Injection-site pain, VAS >5Immediately after treatment1510.0Minor bruisingEarly post-treatment period2013.3Mild asymmetry not requiring interventionMonth 353.3Filler migrationThrough Month 300.0Delayed inflammatory reactionThrough Month 300.0Granuloma or persistent noduleThrough Month 300.0Infection or abscessThrough Month 300.0Vascular compromiseThrough Month 300.0Skin necrosisThrough Month 300.0Visual disturbanceThrough Month 300.0Serious adverse eventThrough Month 300.0Medical or surgical intervention requiredThrough Month 300.0Notes: Participants could experience more than one mild treatment-emergent event; therefore, the event categories were not mutually exclusive. All reported events were mild, localized, and self-limiting. No serious or treatment-requiring complication was observed during the three-month follow-up.Abbreviations: SD, standard deviation; VAS, Visual Analog Scale. Short-Term Safety and Tolerability Outcomes Following Nonsurgical Rhinoplasty (n = 150) Notes: Participants could experience more than one mild treatment-emergent event; therefore, the event categories were not mutually exclusive. All reported events were mild, localized, and self-limiting. No serious or treatment-requiring complication was observed during the three-month follow-up. Abbreviations: SD, standard deviation; VAS, Visual Analog Scale. No serious or treatment-requiring adverse event occurred. No vascular compromise, skin necrosis, visual disturbance, infection, abscess, granuloma, delayed inflammatory reaction, or filler migration was observed during the three-month follow-up. Five participants developed mild asymmetry at Month 3, and none required intervention. Aesthetic Improvement and Patient Satisfaction Significant improvement in appearance during the study was seen across all time periods. The Global Aesthetic Improvement Scale (GAIS) was used to rate participants as “Improved” or “Very Improved” at Month 1, with 86.7% achieving such a rating (Table 3). At Month 3, 125 participants (83.3%) maintained these ratings, Satisfaction was maintained across the entire follow-up period. At Month 1, 135 participants (90.0%) reported satisfaction scores of 4 or 5 on the Likert scale and at Month 3, 130 participants (86.7%) reported the same satisfaction scores of 4 or 5 on the Likert scale. Objective measurements showed a total increase of nasal tip projection over 1.5 mm in 105 patients (70.0%) and increases of dorsal height over 2.0 mm in 95 patients (63.3%).Table 3Aesthetic Improvement and Patient Satisfaction (n = 150)OutcomeTime PointFrequency, nPercentage, %GAIS improved/very improvedMonth 113086.7Month 312583.3Satisfaction score of 4–5Month 113590.0Month 313086.7Tip projection increase >1.5 mmMonth 110570.0Dorsal height gain >2.0 mmMonth 19563.3Mild asymmetryMonth 353.3Filler migrationAny follow-up visit00.0 Table 3Aesthetic Improvement and Patient Satisfaction (n = 150)OutcomeTime PointFrequency, nPercentage, %GAIS improved/very improvedMonth 113086.7Month 312583.3Satisfaction score of 4–5Month 113590.0Month 313086.7Tip projection increase >1.5 mmMonth 110570.0Dorsal height gain >2.0 mmMonth 19563.3Mild asymmetryMonth 353.3Filler migrationAny follow-up visit00.0 Aesthetic Improvement and Patient Satisfaction (n = 150) Procedural Characteristics and Correlation with Satisfaction The mean filler volume administered was 0.85 ± 0.23 mL (range 0.3–1.2 mL). The average time of the procedures was 22.7 ± 5.4 minutes (Table 4). A touch-up procedure was only needed by 10 (6.7%) of the participants. There was a moderate positive correlation between the amount of filler and the degree of patient satisfaction (r = 0.41, p = 0.03), which indicated that there was a positive relationship between the amount of filler volume and patient satisfaction, with a greater amount of structural augmentation leading to higher subjective satisfaction.Table 4Procedural Characteristics (n = 150)VariableValueMean filler volume0.85 ± 0.23 mLVolume range0.3–1.2 mLProcedure duration22.7 ± 5.4 minTouch-up procedures10 (6.7%)Volume vs Satisfaction Correlationr = 0.41, p = 0.03 Table 4Procedural Characteristics (n = 150)VariableValueMean filler volume0.85 ± 0.23 mLVolume range0.3–1.2 mLProcedure duration22.7 ± 5.4 minTouch-up procedures10 (6.7%)Volume vs Satisfaction Correlationr = 0.41, p = 0.03 Procedural Characteristics (n = 150) Follow-Up Compliance and Adverse Events Follow-up compliance was 100% at Day 2, Week 2, Month 1, and Month 3. At Day 2, 20 participants had minor bruising or localized tenderness. At Week 2, five participants had mild residual local reactions. No adverse event was reported at Month 1. At Month 3, five participants had mild asymmetry that did not require treatment. No filler migration, serious adverse event, or treatment-requiring complication was observed (Table 5).Table 5Follow-Up Compliance and Adverse EventsFollow-Up VisitCompliance, %Reported Adverse EventParticipants, nDay 2100Minor bruising or localized tenderness20Week 2100Mild residual local reaction5Month 1100No adverse events reported0Month 3100Mild asymmetry not requiring intervention5 Table 5Follow-Up Compliance and Adverse EventsFollow-Up VisitCompliance, %Reported Adverse EventParticipants, nDay 2100Minor bruising or localized tenderness20Week 2100Mild residual local reaction5Month 1100No adverse events reported0Month 3100Mild asymmetry not requiring intervention5 Follow-Up Compliance and Adverse Events Injection Characteristics and Device Utilization The most common anatomical area treated was the nasal dorsum (125 participants, 83.3%) followed by the nasal tip (105 participants, 70.0%), the supratip (55 participants, 36.7%) and the radix (35 participants, 23.3%). Ninety participants (60.0%) used blunt cannulas while 60 participants (40.0%) used sharp needles (Table 6 and Table 7).Table 6Distribution of Injection Sites (n = 150)Nasal SubunitFrequency (n)Percentage (%)Dorsum12583.3Tip10570.0Supratip5536.7Radix3523.3 Table 7Injection Device Utilization (n = 150)DeviceFrequency (n)Percentage (%)Blunt Cannula9060.0Sharp Needle6040.0 Table 6Distribution of Injection Sites (n = 150)Nasal SubunitFrequency (n)Percentage (%)Dorsum12583.3Tip10570.0Supratip5536.7Radix3523.3 Distribution of Injection Sites (n = 150) Table 7Injection Device Utilization (n = 150)DeviceFrequency (n)Percentage (%)Blunt Cannula9060.0Sharp Needle6040.0 Injection Device Utilization (n = 150) Discussion This pilot clinical study evaluated the short-term safety, tolerability, and preliminary effectiveness of a hybrid injectable formulation composed of regenerated biodegradable polymeric microspheres combined with cross-linked hyaluronic acid for nonsurgical rhinoplasty. Overall, the findings demonstrated a favorable short-term safety profile, high patient satisfaction, and measurable aesthetic improvement during the three-month follow-up period. The demographic characteristics of the study population were broadly consistent with previously reported nonsurgical rhinoplasty cohorts, in which younger and middle-aged adults represent the majority of individuals seeking minimally invasive aesthetic enhancement.23–25 Although female participants constituted the majority of the study population, demographic variables such as age, sex, and Fitzpatrick skin type were not associated with clinically meaningful differences in treatment outcomes. These observations suggest that the effectiveness and tolerability of the investigated filler may be influenced more by procedural factors and anatomical characteristics than by baseline demographic variables, although larger studies are needed to confirm these findings. A key finding of this study was the favorable short-term safety and tolerability profile of the hybrid formulation. Most participants completed follow-up without clinically significant adverse events, and reported complications were limited to transient and self-limiting reactions such as mild erythema and bruising. No cases of vascular compromise, skin necrosis, visual symptoms, granuloma formation, or clinically significant filler migration were observed during the study period. These findings are consistent with previous reports demonstrating low rates of serious complications following hyaluronic acid-based nonsurgical rhinoplasty when appropriate patient selection and injection techniques are employed.26 The absence of delayed inflammatory reactions during the three-month follow-up period is encouraging and may indicate satisfactory early tissue acceptance of the investigated formulation. However, because delayed-onset inflammatory responses and foreign-body reactions may occur months after treatment, longer-term follow-up is required before definitive conclusions regarding long-term safety can be established. Consequently, the present findings should be interpreted as evidence of favorable short-term tolerability rather than comprehensive long-term safety. The immediate improvement in nasal contour was most likely related to the volumetric and structural properties of the cross-linked HA component. The proposed longer-term contribution of PCL and PLA microspheres would depend on gradual polymer degradation and host-tissue responses involving inflammatory cells, fibroblasts, and extracellular-matrix deposition. However, the present study did not include histological examination, collagen quantification, imaging of polymer degradation, or laboratory-based biocompatibility assessment. Therefore, the current clinical findings cannot confirm neocollagenesis, tissue regeneration, or improved tissue integration. Regenerative biomaterials are generally intended to provide temporary structural support while permitting interaction with surrounding tissues. Evidence from collagen membranes and other biodegradable biomaterials suggests that material composition, degradation behaviour, vascularization, cellular response, and the local tissue environment influence successful tissue integration. However, evidence from collagen membranes or other tissue-repair applications cannot be directly extrapolated to an injectable PCL–PLA–HA nasal filler.27 Such evidence provides only general biological context and does not demonstrate regenerative effectiveness of the formulation evaluated in this study. High levels of patient satisfaction and aesthetic improvement were observed throughout follow-up. More than 80% of participants demonstrated improvement on both clinician-assessed and patient-reported outcome measures. These findings are comparable to outcomes reported in previous studies of hyaluronic acid-based fillers used for nonsurgical rhinoplasty.23–26 The observed improvements likely reflect the ability of the hybrid formulation to provide immediate structural augmentation while maintaining contour stability during the early post-treatment period. Objective measurements demonstrated increases in nasal tip projection and dorsal height in most participants. These anatomical changes support the clinical observations of improved nasal contour and profile harmony reported by both patients and evaluators. The low frequency of asymmetry and migration further suggests that the formulation provided adequate positional stability during the follow-up period, although comparative studies are required to determine whether hybrid polymer-enhanced fillers offer advantages over conventional hyaluronic acid products. Although no granuloma, persistent nodule, or delayed inflammatory reaction was observed during three months, this period was insufficient to exclude later biomaterial-associated complications. Biodegradable polymeric particles may produce a controlled host response during degradation, but delayed nodules, persistent inflammation, or foreign-body granuloma may occur in susceptible individuals. The absence of these events during short-term follow-up should therefore not be interpreted as evidence of established long-term immunological safety. The rates of early aesthetic improvement and patient satisfaction observed in the present study appear broadly consistent with reports involving conventional cross-linked HA fillers. However, direct comparison across independent studies is limited by differences in filler characteristics, patient selection, injection technique, outcome definitions, and follow-up duration. Because the present investigation did not include a concurrent comparator group, it cannot determine whether the hybrid formulation provides improved projection, longer correction, greater tissue integration, or a different safety profile compared with HA-only fillers. From a practical perspective, the procedure was well suited to an outpatient clinical setting. Treatment was completed using relatively small filler volumes, procedure times were short, and the need for additional corrective treatment was uncommon. These findings support the feasibility of incorporating the investigated filler into routine nonsurgical rhinoplasty practice. The favorable tolerability profile may also be related to careful patient selection, adherence to established injection principles, and the experience of the treating physicians. The favorable short-term safety findings may have been influenced by treatment-related and selection factors. Procedures were performed by experienced aesthetic physicians using relatively small filler volumes, aseptic precautions, anatomical assessment, and structured follow-up. Participants with active infection, inflammatory disease, relevant hypersensitivity, pregnancy, lactation, anticoagulant use, immunosuppressive therapy, connective-tissue disorders, or keloid tendency were excluded. These factors may have reduced the observed complication rate and limit generalizability to broader patient groups or less-experienced injectors. The present study contributes preliminary clinical evidence regarding the use of hybrid polymer–hyaluronic acid fillers for nasal contouring, an area for which prospective clinical data remain limited. While conventional hyaluronic acid fillers have been extensively studied, relatively few investigations have evaluated formulations incorporating biodegradable polymeric components intended to enhance structural support and tissue integration. Several limitations should be acknowledged. First, this was a single-center uncontrolled pilot study, and the absence of a comparator group prevents assessment of superiority or comparative effectiveness against conventional cross-linked HA fillers. Second, no formal a priori sample-size calculation was performed, and the analyses were exploratory. Third, three months of follow-up was insufficient to evaluate long-term durability, polymer degradation, collagen remodelling, delayed inflammation, foreign-body granuloma, or late migration. Fourth, no histological, imaging-based, or laboratory assessment of tissue integration and biocompatibility was performed. Fifth, detailed product information concerning the PCL-to-PLA ratio, complete carrier composition, HA cross-linking chemistry, rheological characteristics, and full preclinical safety testing was not available in the study records. Sixth, detailed documentation of the injection planes, entry points, aliquot sizes, area-specific volumes, injector experience, and device-selection criteria was unavailable, limiting procedural reproducibility. Seventh, the precise anthropometric landmarks, image-calibration procedure, evaluator blinding, and measurement reliability were not recorded. Finally, experienced injectors and selective eligibility criteria may have contributed to the favorable short-term safety findings and may limit generalizability. Conclusion This prospective, single-center, uncontrolled pilot study demonstrated favorable short-term tolerability, high early patient satisfaction, and measurable improvement in nasal contour following treatment with an investigational PCL–PLA–hyaluronic acid filler. Reported treatment-emergent events were mild and self-limited, and no serious or treatment-requiring complication was observed during three months of follow-up. However, the lack of a comparator group, short follow-up period, absence of formal power calculation, incomplete product characterization, limited procedural documentation, and absence of histological or laboratory-based biocompatibility assessment prevent conclusions regarding superiority, long-term durability, tissue regeneration, polymer degradation, or long-term safety. The findings should therefore be interpreted as preliminary and hypothesis-generating. Larger controlled multicenter studies with complete product characterization and extended follow-up are required.